1Dr. S. M. Harding,Dr. P. B. Harper.The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates[J]. Infection . 1983 (1)
2Brogard JM,Comte F.Pharmacokinetics of the new cephalosporins. Antibiot Chemoth . 1982
3Acred P.The in vitro antibacterial activity of ceftazidime (GR-20263) a comparison with other new β-lactam antibiotics and gentamicin. Ibis .
4Wise R.Comparison of in vitro activity of GR-20263, a novel cephalosporin derivative with activities of other betalactam compound. Ibis . 1980
5Jones RN.Ceftazidime, a pseudomonas-active cephalosporin: in vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. Journal of Antimicrobial Chemotherapy . 1981
6Philips I.Ceftazidime: in vitro antibacterial activity and susceptibility to β-lactanases compared with that of cefotaxime, moxalactam and other β-lactam antibiotics. Ibis . 1981
7Verbist L & Verhaegen J.GR-20263: a new aminothiazolyl-cephalosporin with high activity against pseudomonas and enterobacteriaceae. Antimicrobial Agents and Chemotherapy . 1980
8Harding SM.The comparativc pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. Journal of Antimicrobial Chemotherapy . 1981
9Acuna G.In vitro studies with ceftazidime against aerobic Gram-negative bacilli and Bacteroides fragilis group. Journal of Antimicrobial Chemotherapy . 1981
